TerminatedNCT03774784
A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease
Studying ALECT2 amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alnylam Pharmaceuticals
- Principal Investigator
- Joshua Friedman, MDAlnylam Pharmaceuticals
- Enrollment
- 26 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2020
Study locations (30)
- Clinical Trial Site, Scottsdale, Arizona, United States
- Clinical Trial Site, Tucson, Arizona, United States
- Clinical Trial Site, Denver, Colorado, United States
- Clinical Trial Site, Chicago, Illinois, United States
- Clinical Trial Site, Indianapolis, Indiana, United States
- Clinical Trial Site, Baltimore, Maryland, United States
- Clinical Trial Site, Boston, Massachusetts, United States
- Clinical Trial Site, Detroit, Michigan, United States
- Clinical Trial Site, Rochester, Minnesota, United States
- Clinical Trial Site, Albuquerque, New Mexico, United States
- Clinical Trial Site, Columbus, Ohio, United States
- Clinical Trial Site, Portland, Oregon, United States
- Clinical Trial Site, Houston, Texas, United States
- Clinical Trial Site, San Antonio, Texas, United States
- Clinical Trial Site, St. George, Utah, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03774784 on ClinicalTrials.gov